Ian Davis
Monash University and Eastern Health, VIC, Australia
- This delegate is presenting an abstract at this event.
Professor Ian Davis is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University and Eastern Health, in Melbourne, Australia. He holds honorary appointments with the Ludwig Institute for Cancer Research and Austin Health, and as an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. Prof Davis is a member of the Urology Committee, Skin Cancer Committee and Standing Subcommittee on Research for the Cancer Council Victoria. He is the founder of the COSA Urologic Oncology Group, a member of COSA Board and COSA Council, and is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP). He is chair of the ANZUP Board and of its Scientific Advisory Committee.
Presentations this author is a contributor to:
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: The P3BEP Trial (ANZUP 1302) (#266)
3:00 PM
Howard Chan
Posters1
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) (#269)
3:00 PM
Ian Davis
Posters1
Randomised phase 3 double-blind placebo-controlled trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasound-guided prostate biopsy (Pain-Free TRUS B): ANZUP 1501 (#270)
3:00 PM
Ian Davis
Posters1
Randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer(ANZUP 1301) (#267)
3:00 PM
Howard Chan
Posters1